Compare Stocks: LLY, VKTX, and GPCR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$25.67 -3.8%	$42.95	$25.09 ▼ $94.90	$1.86B	-1.3	1.50 million shs	939,228 shs
LLY Eli Lilly and Company	$1,169.77 -1.6%	$1,173.78	$783.85 ▼ $1,292.65	$1.12T	0.46	2.25 million shs	3.09 million shs
VKTX Viking Therapeutics	$27.73 -2.8%	$32.92	$25.77 ▼ $43.15	$3.60B	0.66	8.81 million shs	8.69 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	-3.79%	-11.42%	-36.43%	-51.89%	-9.77%
LLY Eli Lilly and Company	-1.45%	+1.64%	+4.11%	-1.62%	+38.34%
VKTX Viking Therapeutics	-2.84%	-9.11%	-17.67%	-28.64%	-14.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$25.67 -3.8%	$42.95	$25.09 ▼ $94.90	$1.86B	-1.3	1.50 million shs	939,228 shs
LLY Eli Lilly and Company	$1,169.77 -1.6%	$1,173.78	$783.85 ▼ $1,292.65	$1.12T	0.46	2.25 million shs	3.09 million shs
VKTX Viking Therapeutics	$27.73 -2.8%	$32.92	$25.77 ▼ $43.15	$3.60B	0.66	8.81 million shs	8.69 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	-3.79%	-11.42%	-36.43%	-51.89%	-9.77%
LLY Eli Lilly and Company	-1.45%	+1.64%	+4.11%	-1.62%	+38.34%
VKTX Viking Therapeutics	-2.84%	-9.11%	-17.67%	-28.64%	-14.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GPCR Structure Therapeutics	2.82	Moderate Buy	$110.91	332.06% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,313.43	12.28% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$99.44	258.62% Upside

Current Analyst Ratings Breakdown

Latest LLY, VKTX, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,410.00 ➝ $1,440.00
10/7/2026	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$87.00 ➝ $85.00
10/7/2026	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,419.00 ➝ $1,430.00
10/6/2026	GPCR Structure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
10/1/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/28/2026	LLY Eli Lilly and Company	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,400.00 ➝ $1,500.00
9/23/2026	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$83.00 ➝ $87.00
9/22/2026	VKTX Viking Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/22/2026	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/22/2026	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/22/2026	LLY Eli Lilly and Company	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,250.00

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$24.99 per share	N/A
LLY Eli Lilly and Company	$65.18B	16.89	$24.74 per share	47.29	$28.07 per share	41.67
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GPCR Structure Therapeutics	-$141.20M	-$1.00	N/A	N/A	N/A	N/A	-25.56%	-24.31%	11/5/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	39.25	25.05	1.46	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest LLY, VKTX, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	GPCR Structure Therapeutics	-$0.3250	N/A	N/A	N/A	$50.00 million	N/A
10/29/2026	Q3 2026	LLY Eli Lilly and Company	$9.83	N/A	N/A	N/A	$22.30 billion	N/A
10/28/2026	Q3 2026	VKTX Viking Therapeutics	-$1.07	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	GPCR Structure Therapeutics	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.92	0.59%	+15.18%	23.22%	11 Years
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GPCR Structure Therapeutics	N/A	20.75	20.75
LLY Eli Lilly and Company	1.41	1.35	1.00
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GPCR Structure Therapeutics	91.78%
LLY Eli Lilly and Company	82.53%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
GPCR Structure Therapeutics	5.50%
LLY Eli Lilly and Company	0.14%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GPCR Structure Therapeutics	281	69.62 million	65.79 million	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
VKTX Viking Therapeutics	65	125.99 million	119.31 million	Optionable

LLY, VKTX, and GPCR Headlines

Recent News About These Companies

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

October 8 at 8:18 PM | finance.yahoo.com

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

October 8 at 6:50 PM | zacks.com

Analyst Predicts 316% Upside for Viking Therapeutics Stock Despite 30%+ Loss in Last 3 Months

October 8 at 3:17 PM | tikr.comT

VKTX Advances Obesity Program With New Oral Maintenance Study

October 7 at 1:21 PM | zacks.com

Viking Therapeutics stock fell 3.07 percent as oral trial starts

October 7 at 2:41 AM | ad-hoc-news.deA

Viking Therapeutics Launches Phase 2 Oral VK2735 Maintenance Study

October 6 at 11:40 AM | rttnews.com

Viking Therapeutics Initiates Trial of VK2735 Maintenance Dosing Regimens in Obesity

October 6 at 11:40 AM | finance.yahoo.com

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

October 6 at 11:40 AM | finance.yahoo.com

VKTX Down 16% in a Month: Time to Invest or Exit the Stock?

October 6 at 11:40 AM | finance.yahoo.com

VKTX Down 16% in a Month: Time to Invest or Exit the Stock?

October 6 at 10:16 AM | zacks.com

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

October 6 at 7:05 AM | prnewswire.com

Viking Therapeutics Inc (Derivatives) Price Today in India

October 6 at 6:39 AM | goodreturns.inG

Here Are My Top 4 Stocks to Buy in October

October 5, 2026 | fool.com

Viking Therapeutics (NASDAQ:VKTX) Stock Rating Cut to "Strong Sell" at Wall Street Zen

October 4, 2026 | americanbankingnews.com

Wall Street Zen Downgrades Viking Therapeutics (NASDAQ:VKTX) to Strong Sell

October 4, 2026 | marketbeat.com

Does Viking Therapeutics (VKTX) Pairing VK2735 Data With Fresh Capital Signal A Sharpened Obesity Strategy?

October 2, 2026 | finance.yahoo.com

LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies

October 2, 2026 | zacks.com

Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors

October 1, 2026 | zacks.com

Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors

October 1, 2026 | finance.yahoo.com

3 Emerging Biotech Stocks With Significant Upside Potential (VKTX)

...

October 1, 2026 | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts

September 30, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, VKTX, and GPCR Company Descriptions

Structure Therapeutics NASDAQ:GPCR

$25.67 -1.01 (-3.79%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$25.65 -0.02 (-0.08%)

As of 10/8/2026 07:49 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Eli Lilly and Company NYSE:LLY

$1,169.77 -18.96 (-1.59%)

Closing price 10/8/2026 03:59 PM Eastern

Extended Trading

$1,166.28 -3.49 (-0.30%)

As of 10/8/2026 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Viking Therapeutics NASDAQ:VKTX

$27.73 -0.81 (-2.84%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$27.77 +0.04 (+0.14%)

As of 10/8/2026 07:58 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, VKTX, and GPCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, VKTX, and GPCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, VKTX, and GPCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, VKTX, and GPCR Company Descriptions

Structure Therapeutics NASDAQ:GPCR

Eli Lilly and Company NYSE:LLY

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, VKTX, and GPCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, VKTX, and GPCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, VKTX, and GPCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, VKTX, and GPCR Company Descriptions

Structure Therapeutics NASDAQ:GPCR

Eli Lilly and Company NYSE:LLY

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools